ReBIRTH Study for Women with Peripartum Cardiomyopathy

In the United States, one in 2,000 people experience peripartum cardiomyopathy late in pregnancy or in the first few months after giving birth. This condition causes a weakening of the heart muscle. Most women recover, but some are left with ongoing cardiomyopathy and chronic heart failure.

Saint Luke’s is participating in the ReBIRTH (Randomized Evaluation of Bromocriptine In Myocardial Recovery Therapy) clinical trial to help develop more effective treatments for peripartum cardiomyopathy. This clinical trial evaluates the effectiveness of the medication bromocriptine in treating women with newly diagnosed peripartum cardiomyopathy.

The study is enrolling 200 women with a new diagnosis of peripartum cardiomyopathy who have given birth in the last five months. The trial involves bloodwork and echocardiograms over a period of three years. You can learn more about ReBIRTH by visiting the study page on

To request more information about enrolling in ReBIRTH, complete the below contact form.

Contact Us

10 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Support clinical research

Our participation in the study is made possible by support from Muriel I. Kauffman Women's Heart Center

Charitable gifts can help support innovative women’s heart care and outcomes research. If you'd like to make a donation, please contact Saint Luke's Foundation at 816-932-2252.